• 1
    Capparelli EV, Best BM, Stek A et al. Pharmacokinetics of darunavir once or twice daily during and after pregnancy. 3rd International Workshop on HIV Pediatrics. Rome, Italy, July 15–16, 2011. Poster P72.
  • 2
    Furco A, Gosrani B, Nicholas S et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 2009; 23: 434435.
  • 3
    Ivanovic J, Bellagamba R, Nicastri E et al. Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety. AIDS 2010; 24: 10831084.
  • 4
    Jaworsky D, Thompson C, Yudin MH et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 2010; 15: 677680.
  • 5
    Pacanowski J, Bollens D, Poirier JM et al. Efficacy of darunavir despite low plasma trough levels during late pregnancy in an HIV-hepatitis C virus-infected patient. AIDS 2009; 23: 19231924.
  • 6
    Pinnetti C, Tamburrini E, Ragazzoni E, De Luca A, Navarra P. Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1. Antivir Ther 2010; 15: 127129.
  • 7
    Ripamonti D, Cattaneo D, Cortinovis M, Maggiolo F, Suter F. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int J STD AIDS 2009; 20: 215216.
  • 8
    Sued O, Lattner J, Gun A et al. Use of darunavir and enfuvirtide in a pregnant woman. Int J STD AIDS 2008; 19: 866867.
  • 9
    Colbers A, Moltó J, Ivanovic J et al. A comparison of the pharmacokinetics of darunavir, atazanavir and ritonavir during pregnancy and post-partum. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, March, 2012 [Poster 1013].
  • 10
    Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 9891008.
  • 11
    Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430436.
  • 12
    Stek AM, Mirochnick M, Capparelli E et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20: 19311939.
  • 13
    Scholler-Gyure M, Kakuda TN, Sekar V et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12: 789796.
  • 14
    Notarianni LJ. Plasma protein binding of drugs in pregnancy and in neonates. Clin Pharmacokinet 1990; 18: 2036.
  • 15
    Towers CV, Rumney PJ, Ghamsary MG. Longitudinal study of CD4+ cell counts in HIV-negative pregnant patients. J Matern Fetal Neonatal Med 2010; 23: 10911096.
  • 16
    Cespedes MS, Castor D, Ford SL et al. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. J Acquir Immune Defic Syndr 2013; doi:10.1097/QAI.0b013e318285 [Epub ahead of print].
  • 17
    Conradie F, Zorrilla C, Josipovic D et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med 2011; 12: 570579.
  • 18
    Mirochnick M, Best BM, Stek AM et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56: 412419.
  • 19
    Patterson KB, Dumond JB, Prince HA et al. Protein binding of lopinavir and ritonavir during four phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr 2013; 63: 5158.
  • 20
    Madruga JV, Berger D, McMurchie M et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 4958.